Cumberland Pharmaceuticals Inc (CPIX): Total Liabilities
$52.28M
As of 2025-12-31
$45.77M
As of 2026-06-30
-2.8%
3-year compound annual growth
+1.1%
5-year compound annual growth
+13.2%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $52.28M | -1.4% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $53.04M | +1.0% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $52.52M | -7.8% | 2025-03-07, Balance as of period end |
| 2022-12-31 | $56.95M | +36.1% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $41.86M | -15.6% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $49.59M | -7.2% | 2022-03-11, Balance as of period end |
| 2019-12-31 | $53.46M | -6.4% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $57.12M | +94.9% | 2020-03-20, Balance as of period end |
| 2017-12-31 | $29.31M | +44.5% | 2019-03-12, Balance as of period end |
| 2016-12-31 | $20.28M | +34.3% | 2018-03-09, Balance as of period end |
| 2015-12-31 | $15.10M | +3.0% | 2017-03-13, Balance as of period end |
| 2014-12-31 | $14.65M | +76.1% | 2016-03-14, Balance as of period end |
| 2013-12-31 | $8.32M | -36.1% | 2015-03-09, Balance as of period end |
| 2012-12-31 | $13.03M | +2.7% | 2014-03-11, Balance as of period end |
| 2011-12-31 | $12.68M | -11.5% | 2013-03-12, Balance as of period end |
| 2010-12-31 | $14.34M | n/a | 2012-03-07, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $214.26M | +486.9% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $53.48M | -23.0% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $112.27M | -16.7% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $18.08M | +2.4% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | $77.45M | -49.2% |
Compare CPIX, AQST, XLO, SEPN side by side · Screen every company in Pharmaceutical Preparations ↗